A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer

This study is testing SHR-A1811 — an antibody-drug conjugate that targets HER2 protein on cancer cells and delivers a chemotherapy payload directly to them — in women with triple-negative breast cancer that has spread or cannot be surgically removed. Triple-negative breast cancer does not respond to hormone therapies, so new options are needed. **You may be eligible if...** - You are a woman between 18 and 75 years old - You have confirmed metastatic or locally advanced unresectable triple-negative breast cancer - Your expected survival is at least 12 weeks - Your liver and kidney function are adequate - You have voluntarily agreed to participate **You may NOT be eligible if...** - You have active, untreated brain metastases - You have had another cancer in the past 5 years - You have severe or uncontrolled fluid buildup in body cavities - You received other anti-cancer treatment within 4 weeks before starting the study drug - You have a history of immune deficiency, significant heart disease, or known lung disease (interstitial lung disease) - You have known allergy to humanized antibody therapies Talk to your doctor to see if this trial is right for you.